Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen & Company 39 th Annual Health Care Conference Date: Tuesday, March 12, 2019
View HTML
Toggle Summary Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and others worldwide to recognize Rare Disease Day ® 2019.
View HTML
Toggle Summary Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 3:30 p.m. ET .
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin Provides Corporate Update and 2019 Outlook
Top-line readout of pivotal FORT Study in PKAN expected 3Q19 SAN DIEGO , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2018 to be approximately
View HTML
Toggle Summary Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer
Dr. Dube brings proven track record of global leadership built upon significant commercial and operational success Dr. Dube succeeds Stephen Aselage , who will continue serving on Board SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of
View HTML
Toggle Summary Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT ( 2:00 p.m. ET ).
View HTML
Toggle Summary Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
SAN DIEGO , Dec. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA nephropathy
View HTML
Toggle Summary Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
Top-line data anticipated in the third quarter of 2019 SAN DIEGO , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and efficacy of fosmetpantotenate for the treatment
View HTML